Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | IGF1R | P08069 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.40 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16337268 | 1.00 | AOC3 (0.52) | AOC3KDM4EIGF1RPTPN1HTT | |
| SCHEMBL6283399 | 1.00 | AOC3 (0.52) | AOC3KDM4EIGF1RPTPN1HTT | |
| SCHEMBL21353904 | 0.81 | AOC3 (0.44) | AOC3KDM4EIGF1RPTPN1HTT | |
| SCHEMBL21353903 | 0.81 | AOC3 (0.44) | AOC3KDM4EIGF1RPTPN1HTT | |
| SCHEMBL21393419 | 0.80 | AOC3 (0.47) | AOC3KDM4ESLC6A4SLC6A3MEN1 | |
| SCHEMBL21363635 | 0.80 | AOC3 (0.47) | AOC3KDM4EIGF1RHTTSLC6A4 | |
| SCHEMBL1155019 | 0.78 | AOC3 (0.53) | AOC3KDM4EIGF1RHTTGABBR2 | |
| SCHEMBL6481591 | 0.78 | AOC3 (0.53) | AOC3KDM4EIGF1RHTTGABBR2 | |
| SCHEMBL16340559 | 0.78 | AOC3 (0.53) | AOC3KDM4EIGF1RHTTGABBR2 | |
| SCHEMBL83311 | 0.78 | HTR2A (0.45) | IGF1RSLC6A4SLC6A3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9926269-B2 | Beta-lactam cholesterol absorption inhibitors | RUDJER BOSKOVIC INSTITUTE (HR) | 2018-03-27 | — | — | US | disclosed |
| US-9926269-B2 | Beta-lactam cholesterol absorption inhibitors | RUDJER BOSKOVIC INSTITUTE (HR) | 2018-03-27 | — | — | US | disclosed |
| US-9926269-B2 | Beta-lactam cholesterol absorption inhibitors | RUDJER BOSKOVIC INSTITUTE (HR) | 2018-03-27 | — | — | US | disclosed |
| US-20160355473-A1 | BETA-LACTAM CHOLESTEROL ABSORPTION INHIBITORS | RUDJER BOSKOVIC INSTITUTE (HR) | 2016-12-08 | — | — | US | disclosed |
| US-20160355473-A1 | BETA-LACTAM CHOLESTEROL ABSORPTION INHIBITORS | RUDJER BOSKOVIC INSTITUTE (HR) | 2016-12-08 | — | — | US | disclosed |
| US-20160355473-A1 | BETA-LACTAM CHOLESTEROL ABSORPTION INHIBITORS | RUDJER BOSKOVIC INSTITUTE (HR) | 2016-12-08 | — | — | US | disclosed |
| WO-2015092448-A1 | BETA-LACTAM CHOLESTEROL ABSORPTION INHIBITORS | RUDJER BOSKOVIC INSTITUTE (HR) | 2015-06-25 | — | — | WO | disclosed |
| US-8623873-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623873-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2014-01-07 | — | — | US | disclosed |
| EP-2548874-A2 | Substituted piperazines as CB1 antagonists | Intervet International B.V. (NL) | 2013-01-23 | — | — | EP | disclosed |
| US-20090105208-A1 | Substituted Piperazines as CB1 Antagonists | SCHERING CORPORATION | 2009-04-23 | — | — | US | disclosed |
| US-20090105208-A1 | Substituted Piperazines as CB1 Antagonists | SCHERING CORPORATION | 2009-04-23 | — | — | US | disclosed |
| WO-2009005646-A2 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | SCHERING CORPORATION (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355473-A1 | BETA-LACTAM CHOLESTEROL ABSORPTION INHIBITORS | PCSK9, CETP, NPC1L1 | AOC3 4295/4885KDM4E 4020/4885IGF1R 1530/4885 |
| US-20090105208-A1 | Substituted Piperazines as CB1 Antagonists | CNR1, CNR2, GPR119 | AOC3 3370/4885KDM4E 2473/4885IGF1R 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.